Q4 2024 AtriCure Inc Earnings Call Transcript
Key Points
- AtriCure Inc (ATRC) achieved a 17% revenue growth in 2024, reaching $465 million, with strong performance in pain management, open appendage management, and open ablation franchises.
- The company expanded its adjusted EBITDA from $19 million in 2023 to $31 million in 2024, indicating improved profitability.
- AtriCure Inc (ATRC) launched several new products, including the cryoSPHERE+ and cryoSPHERE MAX probes, which have been well-received and contributed to a 32% growth in the pain management franchise.
- The EnCompass Clamp saw over 50% growth, contributing to a 16% increase in the open franchise for atrial fibrillation treatment.
- AtriCure Inc (ATRC) received FDA approval for the BoxX-NoAF trial, which could expand their market by demonstrating the benefits of prophylactic ablation for post-operative Afib reduction.
- The minimally invasive hybrid AF therapy in the US experienced only 3% growth, facing pressure from the adoption of PFA technologies.
- Gross margin decreased by 39 basis points in Q4 2024 compared to the previous year, primarily due to less favorable geographic and product mix.
- Research and development expenses increased significantly by 68.1% in Q4 2024, partly due to a $12 million payment for a PFA technology licensing agreement.
- The company anticipates continued pressure on its minimally invasive ablation and MIS appendage management franchises in 2025, with expected revenue declines.
- International revenue growth, while strong, contributes to a lower gross margin compared to domestic sales, posing a challenge to overall profitability.
Good afternoon, and welcome to AtriCure's fourth quarter and full year 2024 earnings conference call. This call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments. You may begin.
Great. Thank you. By now you should have received a copy of the earnings press release. If you have not received a copy, please call (513) 644-4484 to have one e-mailed to you.
Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time-to-time in AtriCure's SEC filings.
These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, future
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
